**α-lipoic acid protects against carbon tetrachloride-induced liver cirrhosis through the suppression of the TGF-β/Smad3 pathway and autophagy**

**GUANGWEI LIU**¹, **JIANGKAI LIU**¹, **LINPING PIAN**¹, **SONGLIN GUI**² and **BAOPING LU**¹

¹Spleen, Stomach and Hepatobiliary Department, The First Affiliated Hospital, Henan University of Chinese Medicine, Zhengzhou, Henan 450004; ²Department of Emergency Medicine, Zhengzhou Chinese Medicine Hospital, Zhengzhou, Henan 450007, P.R. China

Received April 25, 2018; Accepted September 28, 2018

DOI: 10.3892/mmr.2018.9719

**Abstract.** α-lipoic acid (ALA) is a naturally occurring antioxidant with protective effects against various hepatic injuries. The aim of the present study was to investigate the mechanisms by which ALA protects the liver from carbon tetrachloride (CCL₄)-induced liver cirrhosis. The widely used liver cirrhosis rat model was established via an intraperitoneal injection of 2 mg/kg 50% CCL₄ three times/week for 8 weeks. Simultaneously, 50 or 100 mg/kg ALA was orally administrated to the rats every day for 8 weeks. The activity of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) was detected in the serum. The pathological liver injuries were analyzed using hematoxylin and eosin and Massori’s trichrome staining. The principal factors involved in the transforming growth factor-β (TGF-β)/mammalian target of rapamycin (mTOR) pathways and in autophagy were examined using reverse transcription–quantitative polymerase chain reaction or western blot analysis. The results demonstrated that ALA protected the liver from CCL₄-induced increase in TGF-β and phosphorylated-Smad3 expression levels. Furthermore, the administration of ALA reversed the CCL₄-induced upregulation of light chain 3II and Beclin-1, and downregulation of p62. The CCL₄-induced suppression of the AKT/mTOR pathway was additionally restored following treatment with ALA. In combination, the results of the present study demonstrated that ALA was able to protect CCL₄-induced liver cirrhosis, an effect that may be associated with inactivation of the TGF-β/Smad3 pathway and suppression of autophagy.

**Introduction**

Liver cirrhosis, caused by progressive hepatocyte injury-induced conversion of normal liver architecture into abnormal nodules, is a common chronic liver disease characterized by hepatic fibrosis. There are a number of factors that may lead to cirrhosis, including alcohol abuse, viral infection, administration of drugs or chemicals (1). In total, one million people succumb to liver cirrhosis every year, accounting for 2% of the total global mortality in 2010 (2,3). Therefore, liver cirrhosis is a significant global health burden. Although the survival of patients with liver cirrhosis has been improved with the development of medicine and surgical procedures (including liver transplantation), developing effective therapeutic agents to prevent the progression of early-stage cirrhosis remains crucial.

Autophagy is a metabolic process occurring in all cell types. Under conditions of cellular stress, defective organelles and excessive components are eliminated to maintain cell survival and cellular activities through autophagy (4,5). Previous studies demonstrated that autophagy may drive the activation of hepatic stellate cells (HSCs) (6,7), a critical event in liver fibrosis (8). Furthermore, inhibition of autophagy may reduce the expression of fibrosis-associated genes, including COL1, α-SMA, β-platelet derived growth factor receptor and matrix metalloproteinase-2 (7). Therefore, selective suppression of autophagic activity may be a promising therapeutic strategy for the prevention of early fibrosis in liver cirrhosis.

α-lipoic acid (ALA) is a naturally occurring thiol antioxidant that protects against acetaminophen-induced liver damage (9), high-fat diet induced-fatty liver (10), concanavalin A-induced hepatitis (11), lipopolysaccharide induced-acute liver injury (12) and liver cirrhosis (13). ALA was able to regulate autophagic activity in certain cases (14,15). However, whether ALA may protect the liver through the regulation of autophagy remains unclear. In the present study, a carbon tetrachloride (CCL₄)-induced liver cirrhosis rat model was...
established and the mechanism of the hepatoprotective effect of ALA was investigated.

Materials and methods

Animals and experimental design. A total of 30 Sprague-Dawley rats (male; 6 week old; weight, 180-200 g) obtained from the Liaoan Chang Sheng Biotechnology Co., Ltd. (Benxi, China) were used in the experiment. After adapting for 1 week under standard animal laboratory conditions (25±2°C; air humidity 50±10%; 12-h light/dark cycle) with free access to food and water, the rats were randomly divided into five groups (6/group): Control group, 100 mg/kg ALA group, CCl₄-treated group, CCl₄+50 mg/kg ALA group and CCl₄+100 mg/kg ALA group. The animal raising and handling procedures were performed in accordance with the Guide for the Care and Use of Laboratory Animals (16) and approved by the Animal Experimental Ethics Committee of the Henan University of Chinese Medicine (Zhengzhou, China).

CCl₄-induced liver cirrhosis model and treatments. A CCl₄-induced liver cirrhosis model was established as previously described (17,18). Rats were intraperitoneally injected with 50% CCl₄ (purchased from Shanghai Aladdin Bio-Chem Technology Co. Ltd., Shanghai, China; 1:1 diluted with olive oil) three times a week for 8 consecutive weeks. In addition to treatment with CCl₄, rats in the CCl₄+50 mg/kg ALA or CCl₄+100 mg/kg ALA groups received 50 or 100 mg/kg ALA (Sangon Biotech Co. Ltd., Shanghai, China) orally every day for 8 weeks. Rats in the control group were intraperitoneally injected with an equal volume of olive oil instead of CCl₄ 3 times a week and received 0.5% sodium carboxymethylcellulose (the solvent of ALA) 0.5 ml orally every day. Rats in the 100 mg/kg ALA group were intraperitoneally injected with an equal volume of olive oil instead of CCl₄ three times a week and received 100 mg/kg ALA orally every day for 8 weeks. At the end of treatment, rats were anesthetized with isoflurane and received 100 mg/kg ALA orally every day for 8 weeks.

Histopathological and immunohistochemical analysis. Liver tissues were fixed in 4% paraformaldehyde for 48 h at 4°C, and were subsequently embedded in paraffin and cut into 5-µm thick sections. Following washing with xylene and hydrating in graded ethanol, the sections were stained with hematoxylin and eosin (H&E) or Masson’s trichrome, according to standard procedures (20). For immunohistochemical analysis, the deparaffinized liver sections were incubated with rabbit anti-α-smooth muscle actin (α-SMA) antibody or rabbit anti-transforming growth factor (TGF)-β antibody (both 1:50; α-SMA, cat. no. 55135-1-AP; TGF-β, cat. no. 21898-1-AP; Wuhan Sanying Biotechnology, Wuhan, China) at 4°C overnight. Subsequently, the specific proteins were detected with biotinylated goat anti-rabbit immunoglobulin G antibody (1:200; cat. no. A0208; Beyotime Institute of Biotechnology, Haimen, China) at 37°C for 30 min. The reactions were finally analyzed with horseradish peroxidase-conjugated streptavidin (Beyotime Institute of Biotechnology). Following visualization using a diaminobenzidine substrate kit (Beijing Solarbio Science & Technology Co., Ltd., Beijing, China), the sections were imaged under a light microscope (BX53; Olympus Corporation, Tokyo, Japan; magnification, x100-200).

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Total RNA from liver tissues was extracted using the China TRIPure Total RNA Extraction kit (BioTeke Corporation, Beijing, China). cDNA was synthesized using Super M-MLV Reverse Transcriptase (BioTeke Corporation) according to the manufacturer's protocol. The hydroxyproline level in liver tissues was measured using a hydroxyproline assay kit (cat. no. A030-2; Nanjing Jiancheng Bioengineering Institute, Nanjing, China), according to the manufacturer's protocol.

Biochemical measurement. Serum was isolated from blood samples by centrifugation at 1,100 x g for 10 min at 4°C. The levels of alanine transaminase (ALT) and aspartate transaminase (AST) in the serum were detected using commercial kits (ALT, cat. no. C009-2; AST, cat. no. C010-2) purchased from Shanghai Aladdin Bio-Chem Technology Co., Ltd., according to the manufacturer's protocol. The hydroxyproline level in liver tissues was measured using a hydroxyproline assay kit (cat. no. A030-2; Nanjing Jiancheng Bioengineering Institute), according to the manufacturer's protocol.

Table I. Primer sequences used in the present study.

| Gene                  | Sequences (5’-3’)               |
|-----------------------|---------------------------------|
| COL1A1                | **Forward:** AGAGGCATAAAGGTCATCGTG  **Reverse:** CAGGAGAACCCAGCAGAGCCA |
| TGF-β                 | **Forward:** CAACATTTCCGTCGTACCTC  **Reverse:** AGGCCCTGATTCCGTCCTCITT |
| Beclin-1              | **Forward:** CAGCGGTCTCAGTTCCCTGT  **Reverse:** TCTTTCTCTCCTGGTTGTC |
| p62                   | **Forward:** AGCGGTACTGCTTCCTACAG  **Reverse:** GCAGGACTCTGATCCTCGTCTT |
| β-actin               | **Forward:** GGAGATTACTGCCCCTGCTGCC  **Reverse:** GCGCGACTCGTACTGCCCTGCTT |

CCl₄, transforming growth factor-β; COL1A1, Collagen α-1(I) chain.
membranes (EMD Millipore, Bedford, MA, USA). Subsequent to blocking with 5% nonfat milk at room temperature for 1 h, the membranes were incubated with specific primary antibodies against α-SMA (1:1,000; cat. no. 55135-1-AP; Wuhan Sanying Biotechnology), TGF-β (1:500; cat. no. 21898-1-AP; Wuhan Sanying Biotechnology), phosphorylated (p)-Smad3 (1:1,000; cat. no. 9520; Cell Signaling Technology, Inc., Danvers, MA, USA), Smad3 (1:1,000; cat. no. 9523; Cell Signaling Technology, Inc.), Beclin-1 (1:1,500; cat. no. 11306-1-AP; Wuhan Sanying Biotechnology), light chain (LC)3II/LC3I (1:1,000; cat. no. 2775; Cell Signaling Technology, Inc.), protein kinase B (AKT; 1:2,000; cat. no. 9272; Cell Signaling Technology, Inc.), p-AKT (1:1,000; cat. no. 4060; Cell Signaling Technology, Inc.), mammalian target of rapamycin (mTOR; 1:1,000; cat. no. 2972; Cell Signaling Technology, Inc.), p-mTOR (1:1,000; cat. no. 2971; Cell Signaling Technology, Inc.) or β-actin (1:500; cat. no. bsm-33139M; BIOSS, Beijing, China) at 4˚C overnight. The membranes were subsequently incubated with horseradish peroxidase (HRP)-conjugated goat anti-rabbit or goat anti-mouse secondary antibody (1:5,000; HRP-conjugated goat anti-rabbit antibody, cat. no. A0208; HRP-conjugated goat anti-mouse antibody, cat. no. A0216; Beyotime Institute of Biotechnology) at 37˚C for 45 min. Finally, the specific proteins were detected using the Beyo Enhanced Chemiluminescent kit (Beyotime Institute of Biotechnology). The relative protein expression level was detected by densitometry using Gel-Pro Analyzer Version 3.0 (Media Cybernetics, Inc., Rockville, MD, USA).

Statistical analysis. Data are presented as the mean ± standard deviation of six independent experiments. Differences between groups were analyzed using one-way analysis of variance, followed by the Bonferroni post hoc test using Image-pro plus 6.0 software (Media Cybernetics, Inc.). *P<0.05 was considered to indicate a statistically significant difference.

Results

ALA alleviates CCl₄-induced liver injury. Histopathological alterations in the liver following treatment with CCl₄ and different doses of ALA were examined by H&E staining (Fig. 1). The livers of healthy and 100 mg/kg ALA-treated
rats exhibited normal liver architecture. Treatment with CCI₄ resulted in visible lesions with the formation of fibrotic septa, the congestion of cytoplasmic vacuolation and hepatocyte necrosis. However, these histopathological alterations induced by CCI₄ were alleviated in the liver of 50- or 100 mg/ml-ALA treated rats. To further examine liver function, the activity of two key enzymes, ALT and AST, in the serum were determined. As presented in Fig. 1B and C, the activity of ALT and AST in CCI₄-treated rats were significantly increased 2.58- and 3.83-fold, respectively, compared with the control rats (P<0.01). By contrast, the activity of ALT and AST was reduced in a dose-dependent manner following treatment with ALA. These results suggested that ALA attenuated CCI₄-induced liver injury.

**ALA attenuates CCI₄-induced hepatic fibrosis.** The collagen deposition of livers was determined using Masson's trichrome staining (Fig. 2A). Liver tissues from normal rats and 100 mg/kg ALA-treated rats demonstrated little collagen deposition, whereas those from CCI₄-treated rats demonstrated dense bundles of collagen fibers around lobules with disordered liver structure. The liver of CCI₄-exposed rats treated with 50 or 100 mg/ml demonstrated decreased collagen deposition. Furthermore, the marker of collagen deposition, hydroxyproline, was additionally significantly increased in the liver of CCI₄-treated rats and decreased in ALA-treated liver-cirrhosis-rats (P<0.01; Fig. 2B). Consistent with these alterations, the mRNA expression level of collagen α₁(Ⅰ) chain (COL1A1) was significantly upregulated in the liver of rats exposed to CCI₄ and significantly reduced following treatment with 50 or 100 mg/ml ALA compared with the CCI₄ group (P<0.01; Fig. 2C). These data indicated that CCI₄-induced severe fibrosis was improved by treatment with ALA.

**ALA suppresses CCI₄-induced activation of HSCs.** The marker of activated HSCs, α-SMA, was detected for the purpose of evaluating the effect of ALA on HSCs. Immunohistochemical
staining results demonstrated that the expression level of α-SMA was significantly increased in the liver of CCl₄-treated rats and was significantly reduced following treatment with ALA (P<0.01; Fig. 3A and B). These alterations in the α-SMA level were additionally confirmed by western blot analysis (Fig. 3C). Therefore, the administration of ALA was demonstrated to result in a decrease in the degree of HSC activation in the liver of CCl₄-treated rats.

**ALA inhibits CCl₄-induced activation of the TGF-β/Smad3 pathway.** To investigate the mechanism behind the hepato-protective effect of ALA, the activation of the TGF-β/Smad3 pathway, an important mediator of liver fibrosis, was detected (22). As presented in Fig. 4A, immunohistochemical analysis demonstrated an increased TGF-β level in the liver tissue of CCl₄-treated rats, when compared with that in the liver tissue of the control rats, while the elevation of TGF-β was decreased by ALA. These alterations in the TGF-β levels were additionally confirmed by RT-qPCR and western blot analysis (Fig. 4B and C). Consistent with the results of TGF-β, the protein level of p-Smad3 in the liver was significantly elevated by CCl₄ (P<0.01) and decreased by ALA. However, the level of Smad3 remained unaltered (Fig. 4D). These results demonstrated that ALA inhibited the activation of the TGF-β/Smad3 pathway in the liver of CCl₄-treated rats.

**ALA suppresses CCl₄-induced autophagy in the liver.** Autophagy has been implicated in CCl₄-induced liver cirrhosis (18) and thus, the expression of autophagy-associated factors was examined in the present study. RT-qPCR and western blot analysis demonstrated that the mammalian autophagy protein, Beclin-1, was significantly increased in the liver of CCl₄-treated rats (P<0.01), and was decreased...
by ALA in a dose-dependent manner (Fig. 5A). In addition, the marker of autophagosome formation, LC3II, which was significantly upregulated following treatment with CCl₄, was additionally significantly reduced following treatment with ALA (P<0.01; Fig. 5B). Furthermore, the expression of the autophagy substrate p62 was significantly decreased following CCl₄ treatment (P<0.01) and increased following the administration of ALA, in a dose-dependent manner (Fig. 5C). In combination, these results suggested that treatment with ALA reversed CCl₄-induced hepatocyte autophagy.

ALA activates the AKT/mTOR pathway in the liver of CCl₄-treated rats. The upstream signaling pathway of autophagy, the AKT/mTOR pathway, was further examined (23). As expected, the p-AKT and p-mTOR expression levels were significantly reduced in the liver of CCl₄-treated rats (P<0.01), and alterations were prominently restored by the administration of ALA (Fig. 6). These results indicated that ALA was able to activate the AKT/mTOR pathway in the liver, which had previously been repressed by treatment with CCl₄.

Figure 4. Treatment with ALA inhibits CCl₄-induced activation of TGF-β/Smad3 pathway in the liver. The expression of TGF-β was detected by (A) immunohistochemical staining, (B) reverse transcription quantitative polymerase chain reaction and (C) western blot analysis. (D) Expression of p-Smad3 and Smad3 were determined by western blotting. Representative images from six independent experiments are presented. Scale bar, 100 µm. Data are expressed as the mean ± standard deviation of six independent experiments. *P<0.01 vs. the control group; **P<0.01 vs. the CCl₄-treated group. ALA, α-lipoic acid; CCl₄, carbon tetrachloride; p-Smad, phosphorylated mothers against decapentaplegic homolog 9; TGF-β, transforming growth factor-β.
Figure 5. Treatment with ALA inhibits CCl₄-induced autophagy in the liver. Expression of (A) Beclin-1, (B) LC3II and (C) p62 were examined by reverse transcription-quantitative polymerase chain reaction or western blot analysis. Representative protein bands from six individual experiments are presented. Data are expressed as the mean ± standard deviation of six independent experiments. **P<0.01 vs. the control group; *P<0.05 and **P<0.01 vs. the CCl₄-treated group. ALA, α-lipoic acid; CCl₄, carbon tetrachloride; LC3, light chain 3.

Figure 6. ALA suppresses the AKT/mTOR pathway in the liver of CCl₄-treated rats. Expression of p-AKT, AKT, p-mTOR and mTOR were detected by western blot analysis. Data are expressed as the mean ± standard deviation of six independent experiments. **P<0.01 vs. the control group; *P<0.05 and **P<0.01 vs. the CCl₄-treated group. p, phosphorylated; mTOR, mammalian target of rapamycin; ALA, α-lipoic acid; CCl₄, carbon tetrachloride; AKT, protein kinase B.
Discussion

The results of the present study demonstrated that treatment with ALA markedly alleviated CCL\textsubscript{4}-induced liver cirrhosis, which became evident through positive histopathological alterations, reduced liver fibrosis and decreased ALT, AST and HSCs activity. Furthermore, it was demonstrated that ALA inhibited the activation of the TGF-β/Smad3 pathway in the liver of CCL\textsubscript{4}-treated rats. CCL\textsubscript{4}-induced hepatocellular autophagy was suppressed by ALA. The administration of ALA additionally promoted the activation of the AKT/mTOR pathway in the liver of CCL\textsubscript{4}-treated rats. These results suggested that the inhibition of autophagy through the regulation of the AKT/mTOR pathway and the repression of the TGF-β/Smad3 pathway may be a mechanism potentially responsible for the protective effect of ALA against CCL\textsubscript{4}-induced liver cirrhosis.

Fibrosis is the final stage of chronic liver injury, characterized by excessive extracellular matrix (ECM) deposition, particularly that of the fibrous protein collagen I. The excessive ECM may destroy normal liver architecture and cause hepatic dysfunction (24). TGF-β is the most powerful cytokine triggering fibrosis-associated signaling in the liver. TGF-β initiates intracellular signaling through the phosphorylation of Smad2/3, which serve as transcription factors and mediate the transcription of COL1A1 (25). Previous studies identified abnormally elevated TGF-β and p-Smad3 expression levels in chronic fibrotic liver disease (26-28). Accordingly, interfering with the TGF-β/Smad3 pathway results in reduced collagen I and ECM production in livers that have been exposed to CCL\textsubscript{4} (27,29,30). Min et al (31) identified that ALA disrupted the TGF-β/Smad3 pathway in the biliary duct ligated-induced hepatic fibrosis mouse model. ALA additionally decreased the TGF-β expression level in the liver that had been exposed to thioacetamide (32). Similar results were obtained in the present study; the administration of ALA suppressed the TGF-β/Smad3 pathway in the liver of CCL\textsubscript{4}-treated rats. In addition, CCL\textsubscript{4}-induced collagen deposition and pathological liver injuries were improved by ALA. These results indicated that ALA was able to protect the liver against cirrhosis through the regulation of the TGF-β/Smad3 pathway.

Insulin plus ALA reduced the mRNA expression level of TGF-β in peripheral blood mononuclear cells of patients with type 1 diabetes, compared with the patients in the insulin treatment group (33). Administration of ALA attenuates glomerular injury in diabetes mellitus by the reduction of nephrogenous TGF-β (34,35). Although the inhibitory effects of ALA on TGF-β expression have been widely reported, the precise mechanisms by which ALA regulates the TGF-β signaling are still not fully understood. Min et al (31) demonstrated that ALA was able to suppress the activity of Smad3 and reduce the binding activity of AP-1 and Sp1, which are downstream mediators of TGF-β. Therefore, it was hypothesized that ALA may decrease the TGF-β expression level through negative feedback regulation. Considering that ALA additionally reduced the mRNA expression level of TGF-β (32), the modulation appears to occur on the transcriptional level.

Under normal circumstances, there is a basal level of autophagy in approximately all cell types; however, when cells were threatened by cellular stress (including cytotoxins and hypoxia), autophagy was rapidly enhanced to provide intracellular nutrients and energy to maintain cell survival (36,37). In the liver, intensive autophagy may drive the activation of HSCs (6,7), which serve a critical role in liver fibrosis. Blocking autophagy was able to inhibit HSC activation and fibrogenesis in cultured cells. Furthermore, the knockout of the HSC-specific Atg7 attenuated CCL\textsubscript{4}/thioacetamide-induced liver fibrosis in mice (6). When autophagy is activated, LC3 transforms from soluble LC3 I to lipid-bound LC3 II, indicating the formation of autophagosomes (38). Beclin-1 is another autophagy marker involved in the formation and maturation of autophagosomes. p62 is a scaffolding protein that may be degraded by autophagy. In the present study, treatment with ALA suppressed CCL\textsubscript{4}-induced autophagy flow, as demonstrated by the decreased Beclin-1 and LC3II/LC3I and increased p62 expression. Therefore, the hepatoprotective effect of ALA appears to be associated with the inhibition of autophagy. The autophagy-inhibitory effect of ALA was additionally reported in 3T3-L1 pre-adipocytes (14), Parkinson's cellular models (39) and hypoxia/reoxygenation-treated H9c2 cells (15).

mTOR, which consists of the two complexes mTORC1 and mTORC2, is known to be a principal negative regulator of autophagy (40). mTORC1 is sensitive to rapamycin and serves as a pivotal checkpoint in modulating the balance between cell growth and autophagy. The PI3K/AKT pathway, which is involved in cell survival, is an upstream modulator of mTORC1 (41). Morales-Ruiz et al (42) suggested that the activation of the PI3K/AKT pathway was disturbed in the livers that had been exposed to CCL\textsubscript{4}. In accordance with previous results, it was demonstrated in the present study that the p-AKT expression level in the liver of CCL\textsubscript{4}-treated rats was reduced compared with the control rats. It was previously demonstrated that ALA was able to protect nerve cells from H\textsubscript{2}O\textsubscript{2}-induced cell death through the activation of the PI3K/AKT/mTOR pathway (43). Pre- or post-treatment with ALA was demonstrated to upregulate p-AKT and p-mTOR in ischemia/reperfusion-injured cerebral endothelial cells (44). Herein, treatment with ALA reversed the CCL\textsubscript{4}-induced inhibition of the AKT/mTOR pathway in the liver, suggesting that ALA may suppress autophagy through the regulation of the AKT/mTOR pathway.

Liver cirrhosis is frequently accompanied by enhanced oxidative stress that is demonstrated by the increase of lipid peroxidation marker, malondialdehyde (MDA) and the decrease of the most studied antioxidant, glutathione (GSH) (45,46). Previously, accumulating evidence suggested that reactive oxygen species (ROS) are the primary intracellular signal transducer in inducing and sustaining autophagy (47-49). Furthermore, ROS was able to inhibit the activation of the AKT/mTOR pathway in vascular smooth muscle cells (50) and human hepatoma cells (51). ALA was originally used as an antioxidant, treatment with ALA significantly restored GSH and antioxidant capacity levels in liver fibrosis rat models (52). Supplementation with ALA additionally reduced MDA level, total oxidant status and lipid peroxides concentration in liver homogenates from high-fat diet rats (53). Therefore, as Rudich et al (54) suggested, ALA may activate the AKT/mTOR pathway and inhibit autophagy by the suppression of oxidative stress.
In conclusion, the present study demonstrated that ALA effectively attenuates liver cirrhosis in CCl4-poisoned rats. Additionally, ALA administration suppressed CCl4-induced autophagy in the liver. CCl4-induced dysregulation of the TGF-β/Smad3 and AKT/mTOR pathways was restored by ALA. These data suggested that ALA may alleviate liver cirrhosis through the inhibition of the TGF-β/Smad3 pathway and autophagy.

Acknowledgements

Not applicable.

Funding

The present study was supported by a grant from the National Natural Science Foundation of China (grant no. 81573933).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

GL designed the present study, performed the animal experiments, analyzed the data and wrote the manuscript. JL and LP performed the animal experiments, the physiological test and the pathological experiments. SG analyzed the data, organized the images and improved the language. BL performed the molecular and protein detection. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The animal raising and handling procedures were performed in accordance with the Guide for the Care and Use of Laboratory Animals and approved by the Animal Experimental Ethics Committee of the Henan University of Chinese Medicine (Zhengzhou, China).

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Bataller R and Brenner DA: Liver fibrosis. J Clin Invest 115: 209-218, 2005.
2. Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, Ezzati M, Shibuya K, Salomon JA, Abdalla S, et al: Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 380: 2197-2223, 2012.
3. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, et al: Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 380: 2095-2128, 2012.
4. Levine B and Kroemer G: Autophagy in the pathogenesis of disease. Cell 132: 27-42, 2008.
5. Cecconi F and Levine B: The role of autophagy in mammalian development: Cell makeover rather than cell death. Dev Cell 15: 344-357, 2008.
6. Thoen LF, Guimaraes EL, Dolle L, Mannaerts I, Najimi M, Sokal E and van Grunsven LA: A role for autophagy during hepatic stellate cell activation. J Hepatol 35: 1353-1360, 2001.
7. Hernandez-Gea V, Ghiassi-Nejad Z, Rozenfeld R, Gordon R, Fied MJ, Yue Z, Czaja MJ and Friedman SL: Autophagy releases lipid that promotes fibrogenesis by activated hepatic stellate cells in mice and in human tissues. Gastroenterology 142: 938-946, 2012.
8. Friedman SL: Mechanisms of hepatic fibrogenesis. Gastroenterology 134: 1655-1669, 2008.
9. Mahmoud YI, Mahmoud AA and Nasser G: Alpha-lipoic acid treatment of acetylaminophen-induced rat liver damage. Biotech Histochem 90: 594-600, 2015.
10. Yang Y, Li W, Liu Y, Sun Y, Li Y, Yao Q, Li J, Zhang Q, Gao Y, Gao L and Zhao J: Alpha-lipoic acid improves high-fat diet-induced hepatic steatosis by modulating the transcription factors SREBP-1, FoxO1 and Nrf2 via the SIRT1/LKB1/AMPK pathway. J Nutr Biochem 25: 1207-1217, 2014.
11. Fei M, Xie Q, Zou Y, He R, Zhang Y, Wang J, Bo L, Li J and Deng X: Alpha-lipoic acid protects mice against concanavalin A-induced hepatitis by modulating cytokine secretion and reducing reactive oxygen species generation. Int Immunopharmacol 53: 55-60, 2016.
12. Tanaka Y, Kaibori M, Miki H, Nakatake R, Tokuhara K, Nishizawa M, Okamura T and Kwon AH: Alpha-lipoic acid exerts a liver-protective effect in acute liver injury rats. J Surg Res 193: 675-683, 2015.
13. Morsy MA, Abdalla AM, Mahmoud AM, Abdelwahab SA and Mahmoud ME: Protective effects of curcumin, α-lipic acid, and N-acetylcysteine against carbon tetrachloride-induced liver fibrosis in rats. J Physiol Biochem 68: 29-35, 2012.
14. Hahm JR, Noh HS, Ha JH, Roh GS and Kim DR: Alpha-lipoic acid attenuates adipocyte differentation and lipid accumulation in 3T3-L1 cells via AMPK-dependent autophagy. Life Sci 100: 125-132, 2014.
15. Cao X, Chen A, Yang P, Song X, Liu Y, Li Z, Wang X, Wang L and Li Y: Alpha-lipoic acid protects cardiomyocytes against hypoxia/reoxygenation injury by inhibiting autophagy. Biochem Biophys Res Commun 441: 935-940, 2013.
16. National Research Council (U.S.): Committee for the Update of the Guide for the Care and Use of Laboratory Animals, Institute for Laboratory Animal Research (U.S.). Committee for the Update of the Guide for the Care and Use of Laboratory Animals. National Academies Press (U.S.): Guide for the Care and Use of Laboratory Animals. National Academies Press, Washington, DC, 2011.
17. Chen Q, Zhang H, Cao Y, Li Y, Sun S, Zhang J and Zhang G: Schisandrin B attenuates CCl4-induced liver fibrosis in rats by regulation of Nrf2-ARE and TGF-β/Smad signaling pathways. Drug Des Devel Ther 11: 2179-2191, 2017.
18. Hung TM, Yuan RH, Huang WP, Chen YH, Lin YC, Lin CW, Lai HS and Lee PH: Increased autophagy markers are associated with ductular reaction during the development of cirrhosis. Am J Pathol 185: 2454-2467, 2015.
19. Parasaruman S, Raveendran D and Kesavan R: Blood sample collection in small laboratory animals. J Pharmacol Pharmacother 1: 87-93, 2010.
20. Huang Y, Wang S, Zhao Y, Lin C, Zhong F, Jin L, He F and Wang H: Histone H3K9 demethylase JMJD1A modulates hepatic stellate cells activation and liver fibrosis by epigenetically regulating peroxisome proliferator-activated receptor γ. FASEB J 29: 1830-1841, 2015.
21. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408, 2001.
22. Gressner AM, Weiskirchen R, Breitkopf K and Dooley S: Roles of TGF-beta in hepatic fibrosis. Front Biosci 7: d793-d807, 2002.
23. Dautert E and Hall MN: mTQR signaling in disease. Cell Biol Int 34: 2454-2467, 2010.
24. Xu F, Liu C, Zhou D and Zhang L: TGF-β/Smad pathway and its regulation in hepatic fibrosis. J Histochem Cytochem 64: 157-167, 2016.
25. Breitkopf K, Godoy P, Ciucan L, Singer MV and Dooley S: TGF-beta/Smad signaling in the injured liver. Z Gastroenterol 44: 57-66, 2006.
Alpha-lipoic acid inhibits hepatic LC3, a Constitutive phosphorylation and nuclear localization of Smad3 are correlated with increased collagen gene transcription in activated hepatic stellate cells. J Cell Physiol 187: 117-123, 2003.

27. Pathil A, Mueller J, Ludwig JM, Wang J, Warth A, Chamulitrat W and Streimmel W: Uroseodeoxycholyl lysophosphatidylethanolamine attenuates hepatofibrogenesis by impairment of TGF-β1/Smad2/3 signalling. Br J Pharmacol 171: 5113-5126, 2014.

28. Perumal N, Perumal M, Halagowder D and Sivasithamparam N: Morin attenuates diethylmaleamate-induced rat liver fibrosis and hepatic stellate cell activation by co-ordinated regulation of Hippo/Yap and TGF-β1/Smad signaling. Biochimie 140: 10-19, 2017.

29. Ganai AA and Husain M: Genistein attenuates D-GalN-induced liver fibrosis/chronic liver damage in rats by blocking the TGF-β1/Smad signaling pathways. Chem Biol Interact 261: 80-85, 2017.

30. Iordanskaia T, Hubal MJ, Koeck E, Rossi C, Schwarz K and Nadler EP: Dysregulation of upstream and downstream transforming growth factor-β transscripts in livers of children with biliary atresia and fibrogenic gene signatures. J Pediatr Surg 48: 2047-2053, 2013.

31. Min AK, Kim MK, Seo HY, Kim HS, Jang BK, Hwang JS, Choi HS, Lee KU, Park KG and Lee IK: Alpha-lipoic acid inhibits hepatic PAI-1 expression and fibrosis by inhibiting the TGF-β1-signaling pathway. Biochem Biophys Res Commun 395: 536-541, 2010.

32. Foo NP, Lin SH, Lee YH, Wu MJ and Wang YJ: α-lipoic acid inhibits liver fibrosis through the attenuation of ROS-triggered signaling in hepatic stellate cells activated by PDGF and TGF-β. Toxicology 282: 39-46, 2011.

33. Hegazy SK, Tolba OA, Mostafa TM, Eida MA and El-Afify DR: α-Lipoic acid and its neuroprotective mechanism in cellular models of Parkinson’s disease. 1. Regulation and significance of autophagy: An overview. J Am Soc Nephrol 13: 108-116, 2002.

34. Melhem MF, Craven PA, Liachenko J and Derubertis FR: Alpha-lipoic acid attenuates hyperglycemia and prevents glomerular mesangial matrix expansion in diabetes. J Am Soc Nephrol 10: 124-133, 2001.

35. Muzushima N, Levine B, Klionsky DJ: Autophagy in diabetes mellitus. Am J Physiol Cell Physiol 298: C776-C785, 2010.

36. Kabeya Y, Muzushima N, Ueno T, Yamamoto A, Kirisako T, Noda T, Komiami E, Ohsumi Y and Yoshimori T: LC3, a mammalian homologue of yeast Apg8p, is localized in autophago-somes membranes after processing. EMBO J 19: 5720-5728, 2000.

37. Zhao H, Zhao X, Liu L, Zhang H, Xuan M, Guo Z, Wang H and Liu C: Neurochemical effects of the R-form of alpha-lipoic acid and its neuroprotective mechanism in cellular models of Parkinson’s disease. Int J Biochem Cell Biol 87: 86-94, 2017.

38. Heras-Sandoval D, Pérez-Rojas JM, Hernández-Damián J and Pedraza-Chaverri J: The role of PI3K/AKT/mTOR pathway in the modulation of autophagy and the clearance of protein aggregates in neurodegeneration. Cell Signal 26: 2694-2701, 2014.

39. Yap TA, Garrett MD, Walton MI, Raynaud F, de Bono JS and Workman P: Targeting the PI3K/AKT/mTOR pathway: Progress, pitfalls, and promises. Curr Opin Pharmacol 8: 393-412, 2008.

40. Morales-Ruiz M, Cejudo-Martín P, Fernández-Varo G, Tugues S, Ros J, Angeli P, Rivera F, Arroyo V, Rodés J, Sessa WC and Jiménez W: Transduction of the liver with activated Akt normalizes portal pressure in cirrhotic rats. Gastroenterology 125: 522-531, 2003.

41. Kamarudin MN, Mohd Raffee NA, Hussein SS, Lo JY, Supriadi H and Abdul Kadir H: (R)-(+)-α-lipoic acid protected NG108-15 cells against H₂O₂-induced cell death through PI3K-Akt/GSK-3β pathway and suppression of NF-κB-cytokines. Drug Des Devel Ther 8: 1765-1780, 2014.

42. Xie R, Li X, Ling Y, Shen C, Wu X, Xu G and Gao X: Alpha-lipoic acid pre- and post-treatments provide protection against in vitro ischemia-reperfusion injury in cerebral endothelial cells via Akt/mTOR signaling. Brain Res 1482: 81-90, 2012.

43. Gutierréz R, Alvarado JL, Presno M, Pérez-Veyna O, Serrano CJ and Yahuaca P: Oxidative stress modulation by Rosmarinus officinalis in CCl4-induced liver cirrhosis. Phytother Res 24: 595-601, 2010.

44. Galicia-Moreno M, Rosique-Oramas D, Medina-Avila Z, Alvarez-Torres T, Falcón D, Higuera-de la Tijera F, BéjarYL, Cordero-Pérez P, Muñoz-Espinosa L, Pérez-Hernández JL, et al: Behavior of oxidative stress markers in alcoholic liver cirrhosis patients. Oxid Med Cell Longev 2016: 9370565, 2016.

45. Filomeni G, Desideri E, Cardaci S, Rotilio G and Ciriolo MR: Under the ROS...thiol network is the principal suspect for autophagy commitment. Autophagy 6: 999-1005, 2010.

46. Filomeni G, De Zio D and Cecconi F: Oxidative stress and autophagy: The clash between damage and metabolic needs. Cell Death Differ 22: 377-388, 2015.

47. Petrović A, Bogojović D, Korač A, Golić I, Jovanović-Stojanov S, Martinović V, Ivanović-Matić S, Stevanović J, Poznanov G and Grigorov I: Oxidative stress-dependent contribution of HMGB1 to the interplay between apoptosis and autophagy in diabetic rat liver. J Physiol Biochem 73: 511-521, 2017.

48. Peng J, He X, Zhang L and Liu P: MicroRNA26a protects vascular smooth muscle cells against H₂O₂-induced injury through activation of the PTEN/Akt/mTOR pathway. Int J Mol Med 42: 1367-1378, 2018.

49. Marín JJ, Hernández A, Revuelta IE, González-Sanchez E, González-Buitrago JM and Perez MJ: Mitochondrial genome depletion in human liver cells abolishes bile acid-induced apoptosis: Role of the Akt/mTOR survival pathway and Bel-2 family proteins. Free Radic Biol Med 61: 218-228, 2013.

50. Fayez AM, Zarkaria S and Moustafa D: Alpha lipoic acid exerts antioxidant effect via Nrf2/HO-1 pathway activation and suppresses hepatic stellate cells activation induced by methotrexate in rats. Biomed Pharmacother 105: 428-433, 2018.

51. Zalejska-Fiolka J, Wielkoszyński T, Rokicki W Jr, Dąbrowska N, Stawiarska-Pięta B, Zalejska-Fiolka J, Hubal MJ, Koeck E, Rossi C, Schwarz K and Nadler EP: Dysregulation of upstream and downstream transduction of the PI3K-Akt/GSK-3β pathway. J Am Soc Nephrol 12: 377-388, 2015.

52. Petrović A, Bogojović D, Korač A, Golić I, Jovanović-Stojanov S, Martinović V, Ivanović-Matić S, Stevanović J, Poznanov G and Grigorov I: Oxidative stress-dependent contribution of HMGB1 to the interplay between apoptosis and autophagy in diabetic rat liver. J Physiol Biochem 73: 511-521, 2017.

53. Feng J, He X, Zhang L and Liu P: MicroRNA26a protects vascular smooth muscle cells against H₂O₂-induced injury through activation of the PTEN/Akt/mTOR pathway. Int J Mol Med 42: 1367-1378, 2018.

54. Marín JJ, Hernández A, Revuelta IE, González-Sanchez E, González-Buitrago JM and Perez MJ: Mitochondrial genome depletion in human liver cells abolishes bile acid-induced apoptosis: Role of the Akt/mTOR survival pathway and Bel-2 family proteins. Free Radic Biol Med 61: 218-228, 2013.

55. Fayez AM, Zarkaria S and Moustafa D: Alpha lipoic acid exerts antioxidant effect via Nrf2/HO-1 pathway activation and suppresses hepatic stellate cells activation induced by methotrexate in rats. Biomed Pharmacother 105: 428-433, 2018.